- Home
- AIIO vs BTAI Comparison
AIIO vs BTAI Comparison
Compare AIIO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | BTAI |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United Arab Emirates | United States |
| Employees | 68 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 35.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | AIIO | BTAI |
|---|---|---|
| Price | $2.70 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 22.3M | 600.4K |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $1.01 |
| 52 Week High | $9.20 | $8.08 |
Technical Indicators
Market Signals| Indicator | AIIO | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 53.79 | 45.26 |
| Support Level | $0.34 | $1.02 |
| Resistance Level | $2.82 | $1.26 |
| Average True Range (ATR) | 1.17 | 0.06 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 24.30 | 21.67 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.